QT Ultrasound Presents Breakthrough Research Results on Quantitative Transmission Ultrasound
Chief Medical Officer, Rajni Natesan, MD, MBA and Principal Scientist, Bilal Malik, Ph.D, will introduce cutting edge research at RSNA 2018
Novato, CA – November 24, 2018 – QT Ultrasound will be among the companies to address the audience at RSNA 2018. The 104th Scientific Assembly of the Radiological Society of North America (RSNA), a conference billed as “Tomorrow’s Radiology Today”, is one of the most important and well attended events by industry leaders, visionaries and game changers in medical imaging. Over 50,000 meeting attendees will get hands-on experience with cutting-edge technology and dive into the latest research, including QT Ultrasound’s quantitative transmission ultrasound.
QT Ultrasound’s Chief Medical Officer, Rajni Natesan, MD, MBA, will be delivering an oral presentation on the “Accuracy of Volumetric Measurements in the Breast: A Study Comparing Ultrasound Tomography and Hand-Held Ultrasound,” demonstrating the benefits of automated true 3D transmission ultrasound technology. This work speaks to the tremendous potential of this technology to accurately and quantitatively assess the volume of masses which, in the breast, can change over time, with implications in improving our estimation of tumor growth and furthering our understanding of tumor response to treatment.
QT Ultrasound’s Principal Scientist, Bilal Malik, Ph.D, will be leading a poster discussion on the “Detection of Calcification in the Breast Using Ultrasound Tomography: A Feasibility Study,” showing that certain calcifications can be effectively detected using the QT Utrasound platform.
Quantitative transmission ultrasound is an emerging trend and the only true 3D, transmission ultrasound technology that uses biomarkers for early detection of breast masses. Transmission ultrasound together with reflection ultrasound provide highly complementary and synergistic information about breast tissue. With images that show clear information about breast tissue, QT Ultrasound’s goal is to identify what is benign and what is problematic. The FDA-cleared QT Ultrasound Breast Scanner can image through dense breasts, with no radiation and no compression.
Conference attendees are encouraged to participate in this valuable learning opportunity.
Rajni Natesan, MD, MBA
Title: Accuracy of Volumetric Measurements in the Breast: A Study Comparing Ultrasound Tomography and Hand-Held Ultrasound
Section: Physics (Ultrasound in Imaging and Radiation Therapy)
Time: Sunday 11/25/2018, 11:15-11:25 AM
Bilal Malik, Ph.D
Title: Detection of Calcification in the Breast Using Ultrasound Tomography: A Feasibility Study
Section: Physics Poster Discussions
Time: Sunday 11/25/2018, 12:30-1:00 PM
About QT Ultrasound
QT Ultrasound® is a privately held company engaged in the research, development, and commercialization of an innovative automated breast imaging system producing high-resolution transmission ultrasound images. The company has received FDA clearance for its QTscan, and the National Institutes of Health (NIH) awarded over $15 million in funding to continue QT Ultrasound research. The company’s clinical trials have been conducted at prestigious institutions in the US and Europe and include ongoing trials at the Marin Breast Health Trial Center in Novato, California. QTscans are now available commercially through the breast imaging centers of QTbreasthealth™.
The QT Ultrasound Breast Scanner is for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient’s breast. The device is not intended to be used as a replacement for screening mammography.